Media & Publications
In the News
Svenskt biotechbolag nära genombrott i behandling mot covid-19 – söker investerare
Researchers at the biotech company Amniotics in Lund has developed a lung specific stem cell for treatment of covid-19. The market for treating lung- and airway diseases is valued at 47 billion Euro. – At present, we are working day and night to finish our process...
Nio projekt för medicin och vaccin mot covid-19 pågår i Medicon Valley. Ett är Amniotics lungspecifika stamceller mot covid-19.
https://www.newsoresund.se/coronaprojekt-medicon-valley/
Protective clothing
Amniotics™ is currently trying to help the local community as much as possible in the coronavirus crisis. We are donating our protective clothing that we use in our GMP laboratory to Region Skåne. These clothes, designed to minimize spread of particles are only used...
Unika stamceller ur fostervatten
Longboat Amniotics had an article in Dagens Industri (text in Swedish), describing our quick progress and ambitions. https://www.di.se/brandstudio/amniotics/unika-stamceller-ur-fostervatten/
Almi Invest invests in Longboat Amniotics
Longboat Amniotics raised SEK 20M in a new investment round in June. The Investment will be used for building a GMP production and further develop the pipeline of tissue specific mesenchymal stem cells. https://lnkd.in/em9KDEshttps://lnkd.in/ePBb_Ca
Biopharma Deal Makers
Longboat Amniotics was featured in the June edition of Biopharma Deal Makers https://lnkd.in/eCknTwP
Press Releases
Amniotics to Present at the Upcoming 2020 Virtual European Biotech Investor Day 2020
Kåre Engkilde, Chief Executive Officer, plans to present an overview of the company and provide a business update at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq. During the 30 (public...
Longboat Amniotics AB has changed its name to Amniotics AB
Longboat Amniotics AB has changed its name to Amniotics AB, to emphasize our commitment to developing innovative and life-changing treatments based on our cell-based products from amniotic fluid. Our pipeline of cell-therapeutics is based on Mesenchymal Stem Cell,...
Longboat Amniotics AB recruits a new CEO in Kåre Engkilde, PhD
The Board of Longboat Amniotics announces a change of CEO in the company as from June 1st. Kåre Engkilde, PhD Immunology, currently working for Agilent Technologies in Denmark where he is Development Manager, Clinical & Medical Affairs, is appointed as Longboat’s...
Fast Development in Longboat Explorers AB
Fast Development in Longboat Explorers AB In March, Longboat Explorers AB has graduated from the Incubator Environment of SmiLe in Lund and it has become “Alumni”. This is in recognition of the company’s fast development from the initial development phase to a...
The CEO of Longboat Explorers, Anders Månsson, is invited for a panel debate on the future of Swedish Life Science
The CEO of Longboat Explorers, Anders Månsson, is invited to and will participate, December 5. 2017, in "Life Science dagen" (Life Science Day) in Stockholm hosted by the leading Swedish Business paper "Dagens Industri" and the leading Life Science paper "Dagens...
New scientific publication underpins Longboat’s Business Model
Recently a peer reviewed article was published in Stem Cell Research & Therapy (see link below) that underpins the intended business model of Longboat Explorers AB. The article concludes that Mesenchymal Stem Cells (sometimes also referred to as Mesenchymal...